Effectiveness of thymoquinone in the treatment of experimental asthma
doi: 10.7417/CT.2013.1559
di
S. Kalemci, S. Cilaker Micili, T. Acar, T. Senol, N. Dirican, G. Omeroglu, A. Bagriyanik, G. Kamaci, O. Yilmaz
Background. Thymoquinone (TQ), the main active constituent of
the volatile oil extracted from Nigella sativa’s seeds, is used for the
treatment of inflammatory diseases and exhibits a variety of pharmacological
effects. Methods. Twenty-eight BALB/c female mice were divided into
four groups: I (sham-operated control group), II, III, and IV. All groups
except for the sham-operated group were sensitized and challenged
with ovalbumin. The sham-operated group received nebulized saline in
challenge period. Mice in groups III and IV were administered TQ at a
dose of 3 mg/kg and dexamethasone 1 mg/kg, respectively, intraperitoneally
once a day for the final 5 days of the challenge period. Animals
were sacrificed 24 h after the last drug administration and the airway
samples were evaluated histologically by light microscopy. Results. All histological parameters in Group III, similar to Group
IV, were improved when compared to Group II. All variables except
numbers of goblet cells were found to be significantly better in Group
III and Group IV compared to Group II. Conclusions. In our study, we demonstrated that TQ administration
alleviates the pathological changes of chronic asthma. TQ might be a
promising therapy for asthma in the future. Clin Ter 2013; 164(3):e155-
158. doi: 10.7417/CT.2013.1559
ATTENZIONE: per accedere al servizio
di consultazione online dei file pdf occorre essere
abbonati alla rivista ed aver abilitato il propriopin.
Se non siete ancora abbonati potete abbonarvi e ricevere il pin attraverso
il nostro online
store.
Per l'attivazione del pin ricevuto, contattare ordini@seu-roma.it.
